Andere Sprachen InnoCan Pharma Corporation

Aktien

A2PSPW

CA45783P1027

INNO

Markt geschlossen - Canadian Securities Exchange Andere Börsenplätze 21:18:15 18.04.2024			% 5 Tage	% 1. Jan.
0.275 ^CAD	0.00%		-6.78%	-11.29%

01.04.	InnoCan Pharma Corporation meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
25.03.	Innocan Pharma Corporation gibt die Unterzeichnung eines Abkommens mit der Hebräischen Universität bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M	01.04.
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	25.03.
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval	25.03.
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.	25.03.
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million	15.03.
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding	14.03.
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain	05.03.
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study	05.03.
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding	05.03.
InnoCan Pharma Corporation Announces Study Findings That Lpt-Cbd Maintain Its Prolonged Release in Rabbits	26.02.
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits	26.02.
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024	20.02.
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights	13.02.
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST	05.02.
Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration	12.12.
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29.11.
InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd.	29.11.
InnoCan Pharma Brief: Reporting US$4.083 Million In Revenues for Q3 2023 Vs US$749,000 for Q3 2022, representing an increase of 445%	29.11.
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022	29.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen InnoCan Pharma Corporation

Aktien

A2PSPW

CA45783P1027

INNO

Andere Sprachen

Filter